Unite with Fellow Investors
Choose the Best Attorney
Follow Case Progress
id: 867, Created by Polina Foster, Scout
Scynexis (SCYX) Allergic Medicines Case
What do I get by joining?
- You will get case updates and receive a payout in case of success
- If you would like to actively participate, you will be connected to the attorney
- No, you do not pay anything out of your pocket neither to us nor to attorney
D. New JerseyCourt
- Scynexis recalled its medicines due to potential allergic reactions.
- On September 26, 2023, the truth came out, leading to a 11% $SCYX fall.
On September 25, 2023, Scynexis recalled its antifungal medication ibrexafungerp and temporarily halted clinical trials due to contamination risk.
This was caused by an unwanted substance found during production that could lead to allergic reactions and hypersensitivity.
This news caused $SCYX fall by 11% and $9.29M loss of market cap, damaging shareholders.
Given all this information, investors have reason to suspect that Scynexis misled about the effectiveness and safety of its drug.
Shock Event Date
26 September 2023
07 November 2023
Lead Plaintiff Deadline
06 January 2024